S&P 500   4,577.10
DOW   34,639.79
QQQ   389.91
S&P 500   4,577.10
DOW   34,639.79
QQQ   389.91
S&P 500   4,577.10
DOW   34,639.79
QQQ   389.91
S&P 500   4,577.10
DOW   34,639.79
QQQ   389.91
NASDAQ:REGN

Regeneron Pharmaceuticals Stock Forecast, Price & News

$634.00
+3.41 (+0.54%)
(As of 12/2/2021 04:00 PM ET)
Add
Compare
Today's Range
$622.49
$640.03
50-Day Range
$543.48
$654.40
52-Week Range
$441.00
$686.62
Volume
563,208 shs
Average Volume
848,368 shs
Market Capitalization
$68.18 billion
P/E Ratio
10.12
Dividend Yield
N/A
Beta
0.19
30 days | 90 days | 365 days | Advanced Chart
Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Regeneron Pharmaceuticals logo

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Headlines

COVID: Second Omicron variant case identified in Minnesota
December 2, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:REGN
CUSIP
75886F10
Employees
9,123
Year Founded
1988

Sales & Book Value

Annual Sales
$8.50 billion
Cash Flow
$33.80 per share
Book Value
$160.48 per share

Profitability

Net Income
$3.51 billion
Pretax Margin
59.42%

Debt

Price-To-Earnings

Miscellaneous

Free Float
94,292,000
Market Cap
$68.18 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
12/03/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/04/2022

Social Links


MarketRank

Overall MarketRank

2.50 out of 5 stars

Medical Sector

120th out of 1,391 stocks

Pharmaceutical Preparations Industry

49th out of 669 stocks

Analyst Opinion: 3.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -












Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

Is Regeneron Pharmaceuticals a buy right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Regeneron Pharmaceuticals stock.
View analyst ratings for Regeneron Pharmaceuticals
or view top-rated stocks.

How has Regeneron Pharmaceuticals' stock price been impacted by COVID-19?

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, REGN stock has increased by 36.4% and is now trading at $634.00.
View which stocks have been most impacted by COVID-19
.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, February 4th 2022.
View our earnings forecast for Regeneron Pharmaceuticals
.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported $15.37 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $9.81 by $5.56. The biopharmaceutical company had revenue of $3.45 billion for the quarter, compared to analyst estimates of $2.80 billion. Regeneron Pharmaceuticals had a net margin of 51.65% and a trailing twelve-month return on equity of 50.38%. The business's revenue for the quarter was up 50.5% on a year-over-year basis. During the same period in the previous year, the company earned $7.68 earnings per share.
View Regeneron Pharmaceuticals' earnings history
.

What price target have analysts set for REGN?

16 Wall Street analysts have issued twelve-month price targets for Regeneron Pharmaceuticals' stock. Their forecasts range from $565.00 to $850.00. On average, they expect Regeneron Pharmaceuticals' share price to reach $714.93 in the next twelve months. This suggests a possible upside of 12.8% from the stock's current price.
View analysts' price targets for Regeneron Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the following people:

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals CEO Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among Regeneron Pharmaceuticals' employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and salesforce.com (CRM).

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.76%), Capital World Investors (4.97%), Wellington Management Group LLP (3.15%), Geode Capital Management LLC (1.63%), Putnam Investments LLC (1.26%) and American Century Companies Inc. (1.10%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends for Regeneron Pharmaceuticals
.

Which institutional investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Alliancebernstein L.P., Neuberger Berman Group LLC, Candriam Luxembourg S.C.A., Rockefeller Capital Management L.P., Sumitomo Mitsui Trust Holdings Inc., Tri Locum Partners LP, and FIL Ltd. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, George L Sing, George Yancopoulos, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, N Anthony Coles, P Roy Vagelos, Plew Daniel P Van, and Robert E Landry.
View insider buying and selling activity for Regeneron Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Regeneron Pharmaceuticals stock?

REGN stock was purchased by a variety of institutional investors in the last quarter, including Putnam Investments LLC, BlackRock Inc., Sivik Global Healthcare LLC, Millennium Management LLC, Altshuler Shaham Ltd, Barclays PLC, Handelsbanken Fonder AB, and Sustainable Growth Advisers LP.
View insider buying and selling activity for Regeneron Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $634.00.

How much money does Regeneron Pharmaceuticals make?

Regeneron Pharmaceuticals has a market capitalization of $68.18 billion and generates $8.50 billion in revenue each year. The biopharmaceutical company earns $3.51 billion in net income (profit) each year or $62.63 on an earnings per share basis.

How many employees does Regeneron Pharmaceuticals have?

Regeneron Pharmaceuticals employs 9,123 workers across the globe.

Does Regeneron Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Regeneron Pharmaceuticals: Loop Road Holdings LLC, OSMR Holdings, OSMR International, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.

When was Regeneron Pharmaceuticals founded?

Regeneron Pharmaceuticals was founded in 1988.

What is Regeneron Pharmaceuticals' official website?

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

Where are Regeneron Pharmaceuticals' headquarters?

Regeneron Pharmaceuticals is headquartered at 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at [email protected], or via fax at 914-347-2113.


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.